Gleason Score at Diagnosis Predicts the Rate of Detection of 18F-Choline PET/CT Performed When Biochemical Evidence Indicates Recurrence of Prostate Cancer: Experience with 1,000 Patients

被引:61
作者
Cimitan, Marino [1 ]
Evangelista, Laura [2 ]
Hodolic, Marina [3 ]
Mariani, Giuliano [4 ]
Baseric, Tanja [1 ]
Bodanza, Valentina [1 ]
Saladini, Giorgio [2 ]
Volterrani, Duccio [4 ]
Cervino, Anna Rita [2 ]
Gregianin, Michele [2 ]
Puccini, Giulia [4 ]
Guidoccio, Federica [4 ]
Fettich, Jure [3 ]
Borsatti, Eugenio [1 ]
机构
[1] IRCCS Natl Canc Inst CRO, Nucl Med Unit, Aviano, Italy
[2] IRCCS, Veneto Inst Oncol, Radiotherapy & Nucl Med Unit, I-35128 Padua, Italy
[3] Univ Med Ctr Ljubljana, Dept Nucl Med, Ljubljana, Slovenia
[4] Univ Pisa, Reg Ctr Nucl Med, Pisa, Italy
关键词
F-18-choline PET; Gleason score; prostate cancer; PSA; restaging; RADICAL RETROPUBIC PROSTATECTOMY; LOCAL RECURRENCE; EAU GUIDELINES; CARCINOMA; ANTIGEN; DISEASE; PSA; EXPRESSION; RELAPSE; GLUT-1;
D O I
10.2967/jnumed.114.141887
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The objective of this study was to explore the ability of the initial Gleason score (GS) to predict the rate of detection of recurrent prostate cancer (PCa) with F-18-choline PET/CT in a large cohort of patients. Methods: Data from 1,000 patients who had undergone F-18-choline PET/CT because of biochemical evidence of relapse of PCa between 2004 and 2013 were retrieved from databases at 4 centers. Continuous data were compared by the Student t test or ANOVA, and categoric variables were compared by the chi(2) test. Univariable and multivariable analyses were performed by logistic regression. Results: The GS at diagnosis was less than or equal to 6 in 257 patients, 7 in 347 patients, and greater than 7 in 396 patients. The results of 645 PET/CT scans were positive for PCa recurrence. Eighty-one percent of the positive PET/CT results were found in patients with a PSA level of greater than or equal to 2 ng/mL, 43% were found in patients with a PSA level of 1-2 ng/mL, and 31% were found in patients with a PSA level of less than or equal to 1 ng/mL; 78.8% of patients with positive PET/CT results had a GS of greater than 7. The results of F-18-choline PET/CT scans were negative in 300 patients; 44% had a GS of less than or equal to 6, 35% had a GS of 7, and 17% had a GS of greater than 7. PET/CT results were rated as doubtful in only 5.5% of patients (median PSA, 1.8 ng/mL). When the GS was greater than 7, the rates of detection of F-18-choline PET/CT were 51%, 65%, and 91% for a PSA level of less than 1 ng/mL, 1-2 ng/mL, and greater than 2 ng/mL, respectively. In univariable and multivariable analyses, both a GS of 7 and a GS of greater than 7 were independent predictors for positive F-18-choline PET/CT results (odds ratios, 0.226 and 0.330, respectively; P values for both, <0.001). Conclusion: A high GS at diagnosis is a strong predictive factor for positive F-18-choline PET/CT scan results for recurrent PCa, even when the PSA level is low (i.e., <= 1 ng/mL).
引用
收藏
页码:209 / 215
页数:7
相关论文
共 33 条
[1]   Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer [J].
Apolo, Andrea B. ;
Pandit-Taskar, Neeta ;
Morris, Michael J. .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (12) :2031-2041
[2]  
Bentley G, 2000, MOL UROL, V4, P125
[3]   Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase &lt;1.5 ng/ml? [J].
Castellucci, Paolo ;
Fuccio, Chiara ;
Rubello, Domenico ;
Schiavina, Riccardo ;
Santi, Ivan ;
Nanni, Cristina ;
Allegri, Vincenzo ;
Montini, Gian Carlo ;
Ambrosini, Valentina ;
Boschi, Stefano ;
Martorana, Giuseppe ;
Marzola, Maria Cristina ;
Fanti, Stefano .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (01) :55-63
[4]   International Variation in Prostate Cancer Incidence and Mortality Rates [J].
Center, Melissa M. ;
Jemal, Ahmedin ;
Lortet-Tieulent, Joannie ;
Ward, Elizabeth ;
Ferlay, Jacques ;
Brawley, Otis ;
Bray, Freddie .
EUROPEAN UROLOGY, 2012, 61 (06) :1079-1092
[5]   A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy [J].
Chism, DB ;
Hanlon, AL ;
Horwitz, EM ;
Feigenberg, SJ ;
Pollack, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (02) :380-385
[6]   [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse:: experience in 100 consecutive patients [J].
Cimitan, Marino ;
Bortolus, Roberto ;
Morassut, Sandro ;
Canzonieri, Vincenzo ;
Garbeglio, Antonio ;
Baresic, Tanja ;
Borsatti, Eugenio ;
Drigo, Annalisa ;
Trovo, Mauro G. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (12) :1387-1398
[7]   Endorectal MR imaging MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: Preliminary experience [J].
Coakley, FV ;
Teh, HS ;
Qayyum, A ;
Swanson, MG ;
Lu, Y ;
Roach, M ;
Pickett, B ;
Shinohara, K ;
Vigneron, DB ;
Kurhanewicz, J .
RADIOLOGY, 2004, 233 (02) :441-448
[8]  
Effert P, 2004, ANTICANCER RES, V24, P3057
[9]   Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer A Systematic Review and Meta-Analysis [J].
Evangelista, Laura ;
Zattoni, Fabio ;
Guttilla, Andrea ;
Saladini, Giorgio ;
Zattoni, Filiberto ;
Colletti, Patrick M. ;
Rubello, Domenico .
CLINICAL NUCLEAR MEDICINE, 2013, 38 (05) :305-314
[10]   Time trends in biochemical recurrence after radical prostatectomy: Results of the search database [J].
Freedland, SJ ;
Presti, JC ;
Amling, CL ;
Kane, CJ ;
Aronson, WJ ;
Dorey, F ;
Terris, MK .
UROLOGY, 2003, 61 (04) :736-741